|
Categories |
|
Infectious Diseases |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- Commercial Insight: Herpes and Respiratory Antivirals - Leaders Rise and Fall 20-Oct-2005
In-depth overview and future outlook of the current herpes and respiratory antiviral market (covers HSV/VZV, CMV, influenza and RSV), with a focus on both clinical and commercial factors driving product differentiation and uptake.
------------------------------------------------------------------------------------------------------------------------- |
2- Stakeholder Insight: HIV - A way of life 14-Oct-2005
An overview of the diagnosis, treatment and management of HIV in the seven major markets, with selected patient segmentations provided. Detailed breakdowns of numbers of treated patients and the most frequently prescribed regimens are also included.
------------------------------------------------------------------------------------------------------------------------- |
3- Commercial Insight: HIV - Simplicity and Survival 03-Aug-2005
In-depth assessment of currently marketed HIV antiretrovirals with a focus on NRTI and PI class dynamics, analysis of the potential impact of new fixed-dose combinations on first-line therapy, and older combinations such as Combivir and Trizivir.
------------------------------------------------------------------------------------------------------------------------- |
4-Commercial Insight: Antibacterials - Pharma Strikes Antibac 03-Aug-2005
In-depth overview of the current global antibacterial market with discussion focused on clinical and commercial environmental factors that differentiate the class outlook to 2015.
------------------------------------------------------------------------------------------------------------------------- |
5- Stakeholder Perspectives: Liver Fibrosis/Cirrhosis -
Point of No Return? 11-Oct-2004
A comprehrensive overview of liver fibrosis/cirrhosis
with emphasis on underlying causes such as chronic viral hepatitis
and non-alcoholic fatty liver disease (NAFLD) including NASH.
Assessment of epidemiology and unmet needs
analysis.
------------------------------------------------------------------------------------------------------------------------- |
6- Stakeholder Opinions: Urinary Tract Infections -
Ciprofloxacin Leads the Way
28-July-2004
An overview of the treatment
market for UTIs, with detailed epidemiology, product analyses and
market assessments.
------------------------------------------------------------------------------------------------------------------------- |
7- Stakeholder Opinions: Skin Infections - Where In The
Antibacterial Lifecycle?
17-June-2004
An overview of the community
management of skin infections across the seven major markets,
including disease definitions, class overviews and analysis of
recent market events.
------------------------------------------------------------------------------------------------------------------------- |
8- Commercial Insight: Hepatitis B and C - Awaiting New
Developments
04-June-2004
In-depth commercial analysis of
the hepatitis B & C markets, including detailed product
profiles, sales analysis, forecasts to 2014 and strategic
recommendations for improving product
performance.
------------------------------------------------------------------------------------------------------------------------- |
9- Commercial Insight: Antifungals - More Data, More
Prescriptions
24-May-2004
Examination of the impact of key
events in the systemic antifungal market, such as the patent
expiries of leading products and the launch of several pipeline
drugs, with recommendations for effective portfolio and lifecycle
management.
------------------------------------------------------------------------------------------------------------------------- |
10- Pipeline Insight: HIV - Enter the New Generation
Inhibitors 26-Apr-2004
In-depth appraisal of HIV antiretroviral pipeline
covering Phase I to Phase III candidates in NRTI, NNRTI, PI and EI
classes, including critical appraisal of product profile, clinical
trial design and global forecasts to 2012.
-------------------------------------------------------------------------------------------------------------------------
|
11- Stakeholder Opinions: Community Acquired Respiratory
Tract Infections - Room for Ketek? 16-Mar-2004
An insight into current community treatment of
respiratory tract infections and the likely impact of Aventis's
Ketek.
-------------------------------------------------------------------------------------------------------------------------
|
12- Respiratory Syncytial Virus: Can Antivirals Make the
Grade?
15-Mar-2004
An
assessment of the potential for current and developmental RSV
therapies and prophylaxis.
-------------------------------------------------------------------------------------------------------------------------
|
13- Commercial Perspectives: Fluoroquinolones -
Established Products Drive Market Growth 28-Jan-2004
An
investigation into how key quinolone antibacterials are utilized
across the US and EU.
-------------------------------------------------------------------------------------------------------------------------
|
14- Stakeholder Opinions: HIV/ HBV Co-infection - More
Potency, More Policy 9-Jan-2004
Therapeutic focus on the HIV/HBV co-infected
population.
-------------------------------------------------------------------------------------------------------------------------
|
15- Pipeline Insight: Antibacterials - Select Classes,
Select Uses 15-Dec-2003
Overview of the
antibacterials pipeline, with an analysis of the key products
currently in late-stage clinical trials, including sales forecasts
to 2011.
-------------------------------------------------------------------------------------------------------------------------
|
16- HIV Resistance: Impact and Evolution
1-Dec-2003
An evaluation of the current issues, trends and
monitoring tools available in the field of HIV drug resistance.
Provides a comprehensive overview of the latest antiretrovirals and
their resistance profiles highlighting key areas on which to focus.
-------------------------------------------------------------------------------------------------------------------------
|
17- Stakeholder Opinions: HIV - Reaching the 'Untapped'
Patient Population
13-Nov-2003
global
overview of the estimates of the treated and untreated HIV and AIDS
populations, revealing two key areas on which to focus to reach the
'untapped
market'.
-------------------------------------------------------------------------------------------------------------------------
|
18- Stakeholder Insight: The Hospital Antibacterial Market
- Specialist Products Drive Market Growth 10-Nov-2003
A
quantitative case-record of 10 major antibacterials' use in five key
internal hospital sectors across 7 major regional markets. Product
is acompanied by a number of interactive
add-ons.
-------------------------------------------------------------------------------------------------------------------------
|
19- Tropical Infections: A Status
Update 17-Oct-2003
An overview of epidemiology, diagnosis and treatment
of three key infectious diseases, prevalent in less developed
regions.
-------------------------------------------------------------------------------------------------------------------------
|
| |
| |
